Bristol-Myers Squibb (BMY) Misses Q3 EPS by 2c, Beats on Revenues; Lowers FY17 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bristol-Myers Squibb (BMY) Reports EMA Validates Type II Variation Application for Opdivo (Nivolumab)
October 30, 2017 7:00 AM EDTBristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to expand the current indications for Opdivo (nivolumab) to include the treatment of patients with melanoma who are at high risk of disease recurrence following complete surgical resection. Validation of the... More
SunTrust Robinson Humphrey Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
October 30, 2017 6:47 AM EDTSunTrust Robinson Humphrey upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Hold to Buy with a price target of $75.00 (from $55.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click... More
Bristol-Myers Squibb (BMY) Weakness Unwarranted - JPMorgan
October 26, 2017 1:04 PM EDTJPMorgan maintains Overweight on Bristol-Myers Squibb Co. (NYSE: BMY).
Analyst Chris Schott says the overall results for Q3 were solid and that the weakness in the stock today is unwarranted. The analyst reminds client the next catalyst he sees for upside... More
